dexrazoxane has been researched along with Left Ventricular Dysfunction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andelfinger, G; Caru, M; Curnier, D; Krajinovic, M; Lapointe, MO; Laverdière, C; Périé, D; Raboisson, MJ; Sinnett, D | 1 |
| Abdel-Qadir, H; Amir, E; Fazelzad, R; Lee, DS; Ong, G; Thavendiranathan, P; Tomlinson, G | 1 |
1 review(s) available for dexrazoxane and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Cardiomyopathies; Clinical Trials as Topic; Dexrazoxane; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Network Meta-Analysis; Prenylamine; Ventricular Dysfunction, Left | 2017 |
1 other study(ies) available for dexrazoxane and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
Topics: Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stroke Volume; Survivors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |